$INCY has been mentioned 16 times over the past 12 months by 2 distinct FinTwit voices, with mentions spanning from October 13, 2025 to June 1, 2026. Jacob Plieth (@jacobplieth) accounts for the vast majority of discussion with 16 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 3 mentions. The biotech sector has been the primary focus for $INCY commentary among these voices.

Recent discussion has centered on clinical developments and strategic decisions. Jacob Plieth noted in March 2026 that one of $INCY's Kras G12D inhibitors faced a clinical hold while another ended recruitment after achieving only 10% of its enrollment target. In late May 2026, Plieth commented on Novartis's pelabresib asset swap, suggesting that $NVS should have retained Monjuvi and transferred pelabresib to $INCY instead of the opposite arrangement. Most recent mentions appeared within ASCO 2026 conference discussions in late May and early June.